Atara Biotherapeutics’ MAA for Allogeneic T-cell Immunotherapy Gets EMA Validation

EMA has fully validated the marketing authorization application for Atara Biotherapeutics’ off-the-shelf allogeneic T-cell therapy, tab-cel (tabelecleucel), with an approval decision expected in 2022.